Ofatumumab, a medication approved for multiple sclerosis (MS), may effectively prevent relapses and disability in people with neuromyelitis optica spectrum disorder (NMOSD), according to a study in China. At their last follow-up, about 80% of the 112 patients analyzed were free from relapses, and more than 60% experienced significant reductions…
treatment
A blood test measuring levels of the GPR37 protein may help diagnose neuromyelitis optica spectrum disorder (NMOSD), assess disease severity, and monitor treatment response, according to a new study. The GPR37 test was also able to distinguish NMOSD from multiple sclerosis (MS) and other neurological disorders. “Our findings…
The first time I sat in the infusion chair to receive Ultomiris (ravulizumab-cwvz), I felt something I hadn’t experienced for a long time after being diagnosed with neuromyelitis optica spectrum disorder (NMOSD): hope. I needed this therapy to bring stability back to my life, to spend less time in…
Note: This column describes the author’s own experiences with antidepressants. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. After realizing recently that I should have been more upset about various life situations, I had to reconsider the benefits and…
The activity of an immune-regulating protein is significantly lower just before or during a relapse in people with neuromyelitis optica spectrum disorder (NMOSD), a recent study has found. This discovery could lead to new ways to monitor disease activity and develop treatments. The protein, called the aryl hydrocarbon receptor…
Long-term use of the approved therapy Enspryng (satralizumab) safely and effectively prevented relapses in people with neuromyelitis optica spectrum disorder (NMOSD) who have antibodies against aquaporin-4 (AQP4). That’s according to up to 8.8 years of pooled data from two placebo-controlled Phase 3 clinical trials — SAkuraStar (NCT02073279) and …
Ultomiris (ravulizumab), an approved infusion therapy for adults with neuromyelitis optica spectrum disorder (NMOSD), is closer to being eligible for reimbursement under public drug plans in Canada, according to its developer, Alexion, AstraZeneca Rare Disease. The company signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA).
The infusion therapy Ultomiris (ravulizumab-cwvz) safely and effectively reduces the risk of a relapse in complex cases of neuromyelitis optica spectrum disorder (NMOSD) and may be combined with rituximab for short periods, a case series study shows. For four NMOSD patients at a hospital in Fujiyoshida, Japan, Ultomiris…
Bio-Thera Solutions has closed patient enrollment ahead of schedule for a pivotal Phase 2/3 clinical trial in China of its investigational therapy BAT4406F due to the treatment’s “compelling efficacy” for neuromyelitis optica spectrum disorder (NMOSD). The decision is based on a recommendation from an Independent Data Monitoring Committee…
High levels of two proteins, called FAM3B and PF4V1, are associated with a reduced risk of neuromyelitis optica spectrum disorder (NMOSD), while elevated levels of two other proteins, called CLEC11A and SERPINA1, are linked to increased odds of developing the immune system disease. These are the findings of a…
Recent Posts
- The bra line battle is a wardrobe crisis for women with NMOSD
- New antibody may explain mystery cases of NMOSD-like disease
- Are those mystery aches and pains due to NMOSD or regular life?
- NMOSD therapy linked to fewer attacks, less disability in Chinese study
- Where I go to recharge from the daily challenges of NMOSD